Search - tctmd.com

Displaying 1 - 20 of 29

Sort: Relevancy | Date

News Conference News TCT 2016

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

Yael L. Maxwell

October 31, 2016

Presentation TCT 2016

If Prolonged (>1 year) DAPT Is Chosen: Choosing Between Clopidogrel, Prasugrel and Ticagrelor

Presenter: John A. Bittl, Daniel I. Simon, C. Michael Gibson

October 30, 2016

News Conference News TCT 2015

TUXEDO-India Affirms Superiority of EES in Patients With Diabetes

Todd Neale

October 14, 2015

Presentation TCT 2015

TCT 78: Efficacy of Long-term Ticagrelor in Stented Patients in PEGASUS-TIMI 54

Presenter: Lisa K. Jennings, Neal S. Kleiman, Marc Bonaca

October 13, 2015

Presentation TCT 2015

Debate: What Is the Optimal ADP-Antagonist Preloading Approach in STEMI? Prehospital or Crushed Ticagrelor!

Presenter: Eric Boersma, E. Magnus Ohman, Dimitrios Alexopoulos

October 12, 2015

Presentation TCT 2015

Debate: Should Prasugrel and Ticagrelor Be Used in a Substantial Number of Patients With Stable CAD? No, the Risks Are Real and There Is No Evidence for Benefit!

Presenter: John A. Bittl, E. Magnus Ohman, Jorge F. Saucedo

October 11, 2015

Presentation TCT 2015

Debate: Should Prasugrel and Ticagrelor Be Used in a Substantial Number of Patients With Stable CAD? Yes, the Benefits Outweigh the Risks!

Presenter: John A. Bittl, E. Magnus Ohman, Christoph A. Kaiser

October 11, 2015

Presentation TCT 2015

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Ticagrelor (PEGASUS Trial)!

Presenter: C. Michael Gibson, Marco Valgimigli, Neal S. Kleiman

October 11, 2015

Presentation TCT 2015

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? Oral or Crushed Ticagrelor for All!

Presenter: C. Michael Gibson, Marco Valgimigli, Guido Parodi

October 11, 2015

News Conference News TCT 2015

Experts Debate Optimal Pharmacologic Approach for STEMI Patients

October 11, 2015

News Conference News TCT 2014

Thoughtful Insights at TCT: Uncertainty Surrounds Antithrombotic Therapy in PCI Patients Who Require Anticoagulation

Todd Neale

October 10, 2014

News Conference News TCT 2014

PLATO Subanalysis: Ticagrelor Safe, Effective in Primary PCI

September 15, 2014

Presentation TCT 2014

No: Vorapaxar Is Effective, but Prasugrel and Ticagrelor are Preferred!

Presenter: Dirk Sibbing

September 14, 2014

Presentation TCT 2014

The Case for Selective Use of Prasugrel and Ticagrelor in PCI Patients with Stable CAD

Presenter: Robert A. Harrington, Ajay J. Kirtane, Thomas D. Stuckey, Matthew J. Price

September 14, 2014

Presentation TCT 2013

Mortality Trumps All: Ticagrelor for (Nearly) All!

Presenter: Michel Le May

October 31, 2013

Presentation TCT 2013

Emerging Ticagrelor Data: Insights Into its Safety and Efficacy Profile

Presenter: Dimitrios Alexopoulos

October 31, 2013

News Conference News TCT 2013

Studies Find Differing Benefits of Platelet, Genotype Testing

October 31, 2013

Presentation TCT 2013

Pre-load wtih Platelet ADP Receptor Inhibition in STEMI: Prasugrel, Ticagrelor, Clopidogrel, Or Does it Matter?

Presenter: Michel Le May

October 30, 2013

News Conference News TCT 2013

EUROMAX: Prehospital Bivalirudin Reduces Bleeding in STEMI

October 30, 2013

Presentation TCT 2013

No! Aspirin and Ticagrelor Is a Much Better Option

Presenter: Emmanouil Brilakis

October 28, 2013

Advertisement

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

If Prolonged (>1 year) DAPT Is Chosen: Choosing Between Clopidogrel, Prasugrel and Ticagrelor

TUXEDO-India Affirms Superiority of EES in Patients With Diabetes

TCT 78: Efficacy of Long-term Ticagrelor in Stented Patients in PEGASUS-TIMI 54

Debate: What Is the Optimal ADP-Antagonist Preloading Approach in STEMI? Prehospital or Crushed Ticagrelor!

Debate: Should Prasugrel and Ticagrelor Be Used in a Substantial Number of Patients With Stable CAD? No, the Risks Are Real and There Is No Evidence for Benefit!

Debate: Should Prasugrel and Ticagrelor Be Used in a Substantial Number of Patients With Stable CAD? Yes, the Benefits Outweigh the Risks!

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Ticagrelor (PEGASUS Trial)!

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? Oral or Crushed Ticagrelor for All!

Experts Debate Optimal Pharmacologic Approach for STEMI Patients

Thoughtful Insights at TCT: Uncertainty Surrounds Antithrombotic Therapy in PCI Patients Who Require Anticoagulation

PLATO Subanalysis: Ticagrelor Safe, Effective in Primary PCI

No: Vorapaxar Is Effective, but Prasugrel and Ticagrelor are Preferred!

The Case for Selective Use of Prasugrel and Ticagrelor in PCI Patients with Stable CAD

Mortality Trumps All: Ticagrelor for (Nearly) All!

Emerging Ticagrelor Data: Insights Into its Safety and Efficacy Profile

Studies Find Differing Benefits of Platelet, Genotype Testing

Pre-load wtih Platelet ADP Receptor Inhibition in STEMI: Prasugrel, Ticagrelor, Clopidogrel, Or Does it Matter?

EUROMAX: Prehospital Bivalirudin Reduces Bleeding in STEMI

No! Aspirin and Ticagrelor Is a Much Better Option

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content